| Literature DB >> 20698943 |
Saverio Paltrinieri1, Stefania Cazzaniga, Nazarè Pinto da Cunha, Alessia Giordano.
Abstract
BACKGROUND: Information about the electrophoretic distribution of CK-MM, CK-MB, and CK-BB, serum creatine kinase (CK) isoenzymes that are indicators of skeletal muscle, cardiac muscle, and brain lesions, respectively, and CK macroenzymes (macro-CK1 and macro-CK2) in dogs and cats with and without central neurologic disease is scant and equivocal.Entities:
Mesh:
Substances:
Year: 2010 PMID: 20698943 PMCID: PMC7169260 DOI: 10.1111/j.1939-165X.2010.00242.x
Source DB: PubMed Journal: Vet Clin Pathol ISSN: 0275-6382 Impact factor: 1.180
Figure 1Electrophoretic gels of creatine kinase (CK) in supernatants from homogenized brain, skeletal muscle (skel), and cardiac muscle (heart) of a cat (FEL) and a dog (K9). BB, MB, and MM indicate the 3 isoenzymes, CK‐BB, CK‐MB, and CK‐MM; M1 and M2 indicate the macroenzymes, macro‐CK1 and macro‐CK2, respectively.
Intra‐ and interassay precision of total CK activity (U/L) and of electrophoretic fractions (percentage of total CK activity).
| Total CK Activity (U/L) | CK‐BB (%) | CK‐MB (%) | Macro‐CK1 (%) | CK‐MM (%) | Macro‐CK2 (%) | |
|---|---|---|---|---|---|---|
| Intra‐assay | ||||||
| Dog | ||||||
| Mean | 48 | 15.7 | 1.5 | 1.6 | 60.2 | 21.0 |
| CV (%) | 3.2 | 2.4 | 3.8 | 7.4 | 1.4 | 1.7 |
| Cat | ||||||
| Mean | 278 | 1.1 | 0.8 | 11.9 | 80.6 | 5.6 |
| CV (%) | 3.4 | 5.1 | 7.5 | 3.0 | 0.8 | 3.6 |
| Inter‐assay | ||||||
| Dog | ||||||
| Mean | 44 | 13.7 | 1.2 | 2.2 | 64.4 | 18.4 |
| CV (%) | 9.3 | 2.9 | 9.4 | 12.0 | 1.4 | 2.0 |
| Cat | ||||||
| Mean | 258 | 1.8 | 2.4 | 15.4 | 69.8 | 10.6 |
| CV (%) | 6.9 | 8.6 | 8.8 | 6.0 | 1.7 | 4.4 |
Intra‐ and interassay precision was evaluated based on 3 runs.
Total CK was determined by the CK‐NAC method.
CV, coefficient of variation; CK, creatine kinase; NAC, N‐acetylcysteine.
Median (minimum–maximum) activities of total and fractionated CK (U/L) in serum (frozen at −20°C for <1 month, then thawed once) from healthy dogs and cats and from dogs and cats with central neurologic disease.
| Activity | Dogs | Cats | ||
|---|---|---|---|---|
| Healthy
( | CNS Signs
( | Healthy
( | CNS Signs
( | |
| CK total | 46 | 116 | 289 | 468 |
| (28–172) | (44–194) | (188–469) | (331–804) | |
| CK‐BB | 7 | 37 | 7 | 8 |
| (1–20) | (22–75) | (2–13) | (1–20) | |
| CK‐MB | 1 | 1 | 3 | 3 |
| (0–1) | (0–2) | (1–15) | (0–10) | |
| Macro‐CK1 | 1 | 2 | 35 | 200 |
| (0–7) | (1–2) | (2–219) | (5–550) | |
| CK‐MM | 27 | 66 | 217 | 285 |
| (11–112) | (13–115) | (128–374) | (109–400) | |
| Macro‐CK2 | 12 | 7 | 13 | 12 |
| (3–53) | (3–9) | (1–60) | (2–87) | |
2 dogs with intracranial tumors and 1 with CNS inflammation secondary to leishmaniasis.
†6 cats with neurologic signs associated with feline infectious peritonitis.
P<.01 compared with healthy animals.
Total CK activity was determined by the CK‐NAC method.
CNS, central nervous system; CK, creatine kinase; NAC, N‐acetylcysteine.
Total and fractionated CK activities (U/L) in serum of individual dogs and cats† with central neurologic disease.
| Total CK | CK‐BB | CK‐MB | Macro‐CK1 | CK‐MM | Macro‐CK2 | |
|---|---|---|---|---|---|---|
| Dog 1 |
|
| 0 | 1 |
|
|
| Dog 2 | 116 |
|
| 2 | 66 | 9 |
| Dog 3 | 44 |
| 1 | 2 | 13 | 7 |
| Cat 1 |
|
| 2 |
| 220 | 9 |
| Cat 2 | 331 | 5 |
| 203 |
| 14 |
| Cat 3 | 411 | 10 | 9 | 24 | 350 | 18 |
| Cat 4 | 419 | 6 |
| 5 |
| 7 |
| Cat 5 |
| 1 | 5 | 197 |
| 2 |
| Cat 6 |
|
| 10 |
| 137 |
|
Dogs 1 and 2 had intracranial tumors; dog 3 had CNS inflammation secondary to leishmaniasis.
†All 6 cats had feline infectious peritonitis.
Bolded activities are higher than the maximum determined for healthy animals; underlined activities are less than the minimum determined for healthy animals.
Total CK activity was determined by the CK‐NAC method.
CNS, central nervous system; CK, creatine kinase; NAC, N‐acetylcysteine.
Figure 2Electrophoretic gels of serum creatine kinase (CK) fractions. (A) Mixed sera and supernatants from homogenized tissues, containing all possible bands. (B) Serum from 2 dogs (left, healthy dog; right, dog with leishmaniasis) applied according to the standard protocol. Note the weak bands. (C) Serum from the same 2 dogs as in (B), but applying twice the amount of serum. Weak bands corresponding to CK‐MM, CK‐BB, and macro‐CK2 (M2) are more visible now, especially in the dog with leishmaniasis (arrow). (D) Serum from 2 healthy cats. CK‐MM is the most abundant band, followed by macro‐CK1 (M1).